Dr Paul Brooks, MBA, PhD
Chief Executive Officer
Dr Brooks joined CN Bio Innovations in 2022. He has over 25 years of experience in building businesses and leading high-performance research, product, marketing, and sales teams to develop and commercialize new biotechnology technologies globally for drug discovery, bioproduction and diagnostics.
Dr Brooks has held senior leadership positions in the USA and the UK, including Head of Business Operations and Managing Director of Horizon Discovery Ltd; Chief Commercial Officer and Executive Board member of Oxford Genetics Ltd; Head of Discovery Research Services at MilliporeSigma (Merck KGaA); and Global Marketing Manager at Sigma-Aldrich Corp. Dr Brooks has a BSc in Biochemistry from the University of Wales, a PhD in Molecular Biology from the University of Manchester Institute of Science and Technology (UMIST), and an MBA from the University of Nottingham Business School.
Dr Tomasz Kostrzewski, PhD
VP – Science and Technology
Dr Kostrzewski has more than 15 years of experience in molecular and cellular biology research. He joined CN Bio in 2015 and was promoted to Director of Biology in 2018 with responsibility for biological model development and collaborative research projects with academia, pharma, and regulators. In 2021 he was subsequently promoted to VP – Science and Technology with responsibility for all technical activities, including developing new products, technologies, and assays, as well as contract research services. Dr Kostrzewski has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. He has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications.
Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation, as well as at GlaxoSmithKline working in biopharmaceutical drug discovery and development. Dr Kostrzewski holds three degrees from the University of Sheffield and Imperial College London in Cell and Molecular Biology.
Deepak Singh, BSc
VP – Sales & Marketing
Deepak Singh joins CN Bio Innovations in February 2023. He has over 30 years of commercial experience within the life science industry, leading high-performance sales, support & marketing teams in establishing new technologies and driving global scalability of products & solutions into the markets in drug discovery, bioproduction, research and diagnostics.
Deepak was previously Head of Global Commercial at Horizon Discovery Ltd (A PerkinElmer company); VP EMEA at Pacific Biosciences; Director of EMEA Sales & Marketing at Affymetrix, and Head of UK Sales for the Genetic Analysis unit of Applied Biosystems (A Perkin-Elmer company at the time).
Emily Drea, LLB
General Counsel
Emily Drea joined CN Bio in January 2022 having worked as an in-house lawyer for 10 years at Arm Limited and more recently as Head of Legal at Pelion. Whilst at Arm, Emily held multiple roles which included supporting commercial transactions on a global level, performing numerous product counsel roles, advising on IP licensing issues, and working in collaboration with senior management on the areas of risk management and compliance. At Pelion, Emily led the legal function as it divested from Arm Limited and became its own separate legal entity. Emily is responsible for providing the legal support CN Bio needs to enable it to grow and scale. Emily also holds a Post Graduate Diploma in Intellectual Property Law and Practice from the University of Oxford.
Dr David Scales, PhD, LLM, FRCPath
Non-executive Director
Dr Scales has broad experience in the pharmaceutical, biotech and contract research sectors in senior and non-executive roles. For more than 20 years working for large pharmaceutical companies, Dr Scales’ roles included International VP at GlaxoWellcome, overseeing development staff in the USA, UK, Italy, and Japan. During his tenure at GlaxoWellcome he represented the European pharmaceutical Industry and chaired the Safety Committee for the first two International Conferences on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
Dr Scales moved into the biotechnology sector in 2000 working as R&D director for Strakan Ltd, Charterhouse Therapeutics Ltd, and Antisoma PLC before becoming CEO of Cerogenix Ltd and then GlycoForm Ltd. In January 2013 he joined CN Bio Innovations as Chief Executive. He took on the role as Board advisor to the company in 2016 to then join as Non-Executive Director in 2018. Dr Scales initially trained as a toxicological pathologist, holds three degrees from London University and the Royal Postgraduate Medical School, and is a Fellow of the Royal College of Pathologists.
Maureen Coleman, BSc FAPSGB
Chairman
Maureen is a pharmaceutical scientist with over 40 years of experience in the life science sector in large pharma and smaller innovation-led life science companies. She worked for many years at GSK, starting in pharmaceutical development and becoming VP of Global R&D Strategy Development. More recently, she has been working with investor-backed companies across the life science sector in CEO, Chairman and NED roles and as an Angel Investor.
Raymond Tong, MD, PhD, MBA
Non-executive Director
Raymond began his career in Canada, where he founded a chain of medical clinics in the province of Ontario, and served as its Medical Director & Chief Physician. He then returned to Hong Kong in 1989, and since then has held corporate appointments with multinationals in the medical and pharmaceutical industries. This includes RKR Pharmaceutical, Faulding China and Ball Asia Pacific and CITIC Pacific.
Samantha Macro, PhD, MBA
Chief Financial Officer
Samantha joined CN Bio in 2023. She has over 15 years of experience in life sciences and has worked for therapeutic, tools and reagents companies. She has broad experience, including raising investments and preparing for public listing. Previously, Samantha was VP of Finance at Mestag Therapeutics, SVP of Group Finance at Horizon Discovery Ltd and Finance Director at Johnson Matthey.